DEA Eases Restrictions on CBD Research to Benefit Big Pharma

There was speculation last week that the U.S. Drug Enforcement Administration might be on the verge of downgrading the Schedule I classification of the cannabis plant. Unfortunately, the end result proved the implications behind the rumors were somewhat overstated, as the…


Read article here: High Times